{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T12:34:23Z","timestamp":1792413263206,"version":"4.4.0"},"reference-count":132,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2017,12,22]],"date-time":"2017-12-22T00:00:00Z","timestamp":1513900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2017.01850","type":"journal-article","created":{"date-parts":[[2017,12,22]],"date-time":"2017-12-22T09:29:54Z","timestamp":1513934994000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":195,"title":["Chimeric Antigen Receptors T Cell Therapy in Solid Tumor: Challenges and Clinical Applications"],"prefix":"10.3389","volume":"8","author":[{"given":"Hamid R.","family":"Mirzaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Analiz","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Shepphird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnam","family":"Badie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,12,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"B2","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"key":"B3","doi-asserted-by":"publisher","first-page":"371","DOI":"10.3389\/fimmu.2013.00371","article-title":"Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T cells","volume":"4","author":"Chmielewski","year":"2013","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/PPO.0000000000000034","article-title":"CD28z CARs and armored CARs","volume":"20","author":"Pegram","year":"2014","journal-title":"Cancer J"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2017.1375107","article-title":"Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse","author":"Cummins","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov"},{"key":"B8","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T cell therapy for solid tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu Rev Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","article-title":"Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells","volume":"19","author":"John","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"3905","DOI":"10.1182\/blood-2015-01-621474","article-title":"Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs","volume":"125","author":"Ninomiya","year":"2015","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1182\/blood.V126.23.852.852","article-title":"Identification of PD1 and TIM3 as checkpoints that limit chimeric antigen receptor T cell efficacy in leukemia","volume":"126","author":"Kenderian","year":"2015","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1172\/JCI89455","article-title":"Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy","volume":"127","author":"Beavis","year":"2017","journal-title":"J Clin Invest"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex genome editing to generate universal CAR T cells resistant to PD1 inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e994446","DOI":"10.4161\/2162402X.2014.994446","article-title":"IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo","volume":"4","author":"Koneru","year":"2015","journal-title":"Oncoimmunology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1182\/blood-2010-03-275446","article-title":"Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia","volume":"116","author":"Zhou","year":"2010","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/nm.3286","article-title":"Inhibition of p300 impairs Foxp3+ T regulatory cell function and promotes antitumor immunity","volume":"19","author":"Liu","year":"2013","journal-title":"Nat Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","article-title":"Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity","volume":"2","author":"Wang","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4479","DOI":"10.1172\/JCI69589","article-title":"Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function","volume":"123","author":"Sukumar","year":"2013","journal-title":"J Clin Invest"},{"key":"B19","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1158\/2326-6066.CIR-15-0263","article-title":"Augmentation of CAR T-cell trafficking and antitumor efficacy by blocking protein kinase A localization","volume":"4","author":"Newick","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci Transl Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/mt.2015.119","article-title":"T Cells engineered with chimeric antigen receptors targeting NKG2D ligands display lethal toxicity in mice","volume":"23","author":"VanSeggelen","year":"2015","journal-title":"Mol Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","article-title":"Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor","volume":"17","author":"Moon","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/mtna.2013.32","article-title":"TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy","volume":"9","author":"Grada","year":"2013","journal-title":"Mol Ther Nucleic Acids"},{"key":"B24","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1158\/0008-5472.CAN-12-3913","article-title":"Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice","volume":"73","author":"Chinnasamy","year":"2013","journal-title":"Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1158\/1078-0432.CCR-15-1070","article-title":"Blockade of programmed death 1 augments the ability of human T cells engineered to target NY-ESO-1 to control tumor growth after adoptive transfer","volume":"22","author":"Moon","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"djv146","DOI":"10.1093\/jnci\/djv146","article-title":"Impact of a new fusion receptor on PD-1-mediated immunosuppression in adoptive T cell therapy","volume":"107","author":"Kobold","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"B27","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/CJI.0000000000000064","article-title":"CTLA-4 blockade plus adoptive T cell transfer promotes optimal melanoma immunity in mice","volume":"38","author":"Mahvi","year":"2015","journal-title":"J Immunother"},{"key":"B28","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/sj.gt.3301685","article-title":"Retroviral transduction of human peripheral blood lymphocytes with bcl-XL promotes in vitro lymphocyte survival in pro-apoptotic conditions","volume":"9","author":"Eaton","year":"2002","journal-title":"Gene Ther"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1158\/0008-5472.CAN-04-2006","article-title":"Bcl-2 overexpression enhances tumor-specific T-cell survival","volume":"65","author":"Charo","year":"2005","journal-title":"Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"4677","DOI":"10.1182\/blood-2004-08-3337","article-title":"Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis","volume":"105","author":"Dotti","year":"2005","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.imlet.2008.10.009","article-title":"Knockdown of human bid gene expression enhances survival of CD8+ T cells","volume":"122","author":"Lei","year":"2009","journal-title":"Immunol Lett"},{"key":"B32","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1038\/gt.2012.97","article-title":"Efficient selection of genetically modified human T cells using methotrexate-resistant human dihydrofolate reductase","volume":"20","author":"Jonnalagadda","year":"2013","journal-title":"Gene Ther"},{"key":"B33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.stem.2012.12.006","article-title":"Regeneration of human tumor antigen-specific T cells from iPSCs derived from mature CD8+ T cells","volume":"12","author":"Vizcardo","year":"2013","journal-title":"Cell Stem Cell"},{"key":"B34","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1182\/blood.V99.9.3179","article-title":"Adapting a transforming growth factor \u03b2-related tumor protection strategy to enhance antitumor immunity","volume":"99","author":"Bollard","year":"2002","journal-title":"Blood"},{"key":"B35","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/nbt.2725","article-title":"Reassessing target antigens for adoptive T-cell therapy","volume":"31","author":"Hinrichs","year":"2013","journal-title":"Nat Biotechnol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-017-0444-9","article-title":"Chimeric antigen receptor T cells: a novel therapy for solid tumors","volume":"10","author":"Yu","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/sj.mt.6300104","article-title":"Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma","volume":"15","author":"Park","year":"2007","journal-title":"Mol Ther"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1089\/hum.2012.041","article-title":"Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma","volume":"23","author":"Morgan","year":"2012","journal-title":"Hum Gene Ther"},{"key":"B39","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/jnci\/dju364","article-title":"Selective bispecific T cell recruiting antibody and antitumor activity of adoptive T cell transfer","volume":"107","author":"Kobold","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"B40","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1042\/BST20160037","article-title":"Treatment of metastatic renal cell carcinoma (mRCC) with CAIX CAR-engineered T-cells-a completed study overview","volume":"44","author":"Lamers","year":"2016","journal-title":"Biochem Soc Trans"},{"key":"B41","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1038\/mt.2011.131","article-title":"PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor","volume":"19","author":"Nakazawa","year":"2011","journal-title":"Mol Ther"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/mt.2009.133","article-title":"Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression","volume":"17","author":"Ahmed","year":"2009","journal-title":"Mol Ther"},{"key":"B45","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/cr.2016.81","article-title":"Bifunctional alphaHER2\/CD3 RNA-engineered CART-like human T cells specifically eliminate HER2(+) gastric cancer","volume":"26","author":"Luo","year":"2016","journal-title":"Cell Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-14-1421","article-title":"Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases","volume":"21","author":"Katz","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and safety of IL13Ralpha2-redirected chimeric antigen receptor CD8+ T cells in patients with recurrent glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"B49","doi-asserted-by":"publisher","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"key":"B50","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s10875-012-9689-9","article-title":"Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling","volume":"32","author":"Wilkie","year":"2012","journal-title":"J Clin Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ceb.2008.12.010","article-title":"ErbB receptors and signaling pathways in cancer","volume":"21","author":"Hynes","year":"2009","journal-title":"Curr Opin Cell Biol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrc1667","article-title":"ERBB receptors and cancer: the complexity of targeted inhibitors","volume":"5","author":"Hynes","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1093\/emboj\/19.13.3159","article-title":"The ErbB signaling network: receptor heterodimerization in development and cancer","volume":"19","author":"Olayioye","year":"2000","journal-title":"EMBO J"},{"key":"B55","first-page":"3639","article-title":"Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition","volume":"23","author":"Yano","year":"2002","journal-title":"Anticancer Res"},{"key":"B56","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3389\/fphar.2016.00405","article-title":"Immune responses to epidermal growth factor receptor (EGFR) and their application for cancer treatment","volume":"7","author":"Sasada","year":"2016","journal-title":"Front Pharmacol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1634\/theoncologist.7-suppl_4-31","article-title":"Epidermal growth factor receptor dependence in human tumors: more than just expression?","volume":"7","author":"Arteaga","year":"2002","journal-title":"Oncologist"},{"key":"B58","first-page":"6962","article-title":"Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme","volume":"63","author":"Shinojima","year":"2003","journal-title":"Cancer Res"},{"key":"B59","first-page":"1383","article-title":"Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas","volume":"60","author":"Frederick","year":"2000","journal-title":"Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"2965","DOI":"10.1073\/pnas.89.7.2965","article-title":"Structural alterations of the epidermal growth factor receptor gene in human gliomas","volume":"89","author":"Wong","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B61","doi-asserted-by":"publisher","first-page":"4207","DOI":"10.1073\/pnas.87.11.4207","article-title":"Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma","volume":"87","author":"Humphrey","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B62","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1023\/A:1011177318162","article-title":"The type III epidermal growth factor receptor mutation biological significance and potential target for anti-cancer therapy","volume":"12","author":"Pedersen","year":"2001","journal-title":"Ann Oncol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/1479-5876-3-38","article-title":"The natural history of EGFR and EGFRvIII in glioblastoma patients","volume":"3","author":"Heimberger","year":"2005","journal-title":"J Transl Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e83332","DOI":"10.1371\/journal.pone.0083332","article-title":"EGFRvIII mediates hepatocellular carcinoma cell invasion by promoting S100 calcium binding protein A11 expression","volume":"8","author":"Luo","year":"2013","journal-title":"PLoS One"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1158\/0008-5472.CAN-11-2656","article-title":"Epidermal growth factor receptor variant III contributes to cancer stem cell phenotypes in invasive breast carcinoma","volume":"72","author":"Del Vecchio","year":"2012","journal-title":"Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","first-page":"91","DOI":"10.2174\/1568009023333926","article-title":"Mutant epidermal growth factor receptors as targets for cancer therapy","volume":"2","author":"Lorimer","year":"2002","journal-title":"Curr Cancer Drug Targets"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa0984","article-title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma","volume":"9","author":"O\u2019Rourke","year":"2017","journal-title":"Sci Transl Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"275ra22","DOI":"10.1126\/scitranslmed.aaa4963","article-title":"Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma","volume":"7","author":"Johnson","year":"2015","journal-title":"Sci Transl Med"},{"key":"B69","first-page":"985","article-title":"Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas","volume":"5","author":"Debinski","year":"1999","journal-title":"Clin Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e77769","DOI":"10.1371\/journal.pone.0077769","article-title":"Glioma IL13Ralpha2 is associated with mesenchymal signature gene expression and poor patient prognosis","volume":"8","author":"Brown","year":"2013","journal-title":"PLoS One"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1093\/neuonc\/nou045","article-title":"Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy","volume":"16","author":"Thaci","year":"2014","journal-title":"Neuro Oncol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl J Med"},{"key":"B73","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/nature01392","article-title":"Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab","volume":"421","author":"Cho","year":"2003","journal-title":"Nature"},{"key":"B75","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.2470152","article-title":"Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer","volume":"244","author":"Slamon","year":"1989","journal-title":"Science"},{"key":"B76","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1200\/JCO.1999.17.9.2781","article-title":"Expression of HER2\/erbB-2 correlates with survival in osteosarcoma","volume":"17","author":"Gorlick","year":"1999","journal-title":"J Clin Oncol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11060-008-9534-4","article-title":"Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy","volume":"88","author":"Zhang","year":"2008","journal-title":"J Neurooncol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"5957","DOI":"10.1158\/0008-5472.CAN-06-4309","article-title":"Regression of experimental medulloblastoma following transfer of HER2-specific T cells","volume":"67","author":"Ahmed","year":"2007","journal-title":"Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"7159","DOI":"10.1073\/pnas.84.20.7159","article-title":"Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells","volume":"84","author":"Hudziak","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B80","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1245\/s10434-011-1554-1","article-title":"Her-2\/neu gene amplification in esophageal adenocarcinoma and its influence on survival","volume":"18","author":"Thompson","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ctrv.2006.01.001","article-title":"Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer","volume":"32","author":"Serrano-Olvera","year":"2006","journal-title":"Cancer Treat Rev"},{"key":"B82","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B83","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/ijc.2910500308","article-title":"Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium","volume":"50","author":"Chang","year":"1992","journal-title":"Int J Cancer"},{"key":"B84","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1097\/01.MP.0000056981.16578.C3","article-title":"Value of mesothelin immunostaining in the diagnosis of mesothelioma","volume":"16","author":"Ord\u00f3\u00f1ez","year":"2003","journal-title":"Mod Pathol"},{"key":"B85","first-page":"3862","article-title":"Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas","volume":"7","author":"Argani","year":"2001","journal-title":"Clin Cancer Res"},{"key":"B86","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.ejca.2007.08.028","article-title":"Mesothelin targeted cancer immunotherapy","volume":"44","author":"Hassan","year":"2008","journal-title":"Eur J Cancer"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1158\/1078-0432.CCR-06-2161","article-title":"Mesothelin expression in human lung cancer","volume":"13","author":"Ho","year":"2007","journal-title":"Clin Cancer Res"},{"key":"B88","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1158\/1535-7163.MCT-07-0483","article-title":"Mesothelin is a malignant factor and therapeutic vaccine target for pancreatic cancer","volume":"7","author":"Li","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/sj.bjc.6604964","article-title":"High mesothelin correlates with chemoresistance and poor survival in epithelial ovarian carcinoma","volume":"100","author":"Cheng","year":"2009","journal-title":"Br J Cancer"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1158\/1078-0432.CCR-13-1862","article-title":"Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma","volume":"20","author":"Kachala","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B91","doi-asserted-by":"publisher","first-page":"3566","DOI":"10.1158\/0008-5472.CAN-12-3874","article-title":"Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases","volume":"73","author":"Riese","year":"2013","journal-title":"Cancer Res"},{"key":"B92","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","article-title":"Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience","volume":"24","author":"Lamers","year":"2006","journal-title":"J Clin Oncol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/mt.2013.17","article-title":"Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity","volume":"21","author":"Lamers","year":"2013","journal-title":"Mol Ther"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox182","article-title":"Trivalent CAR T-cells overcome interpatient antigenic variability in glioblastoma","author":"Bielamowicz","year":"2017","journal-title":"Neuro Oncol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/0167-5699(93)90262-J","article-title":"Costimulation of T cells for tumor immunity","volume":"14","author":"Chen","year":"1993","journal-title":"Immunol Today"},{"key":"B96","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/mt.2009.210","article-title":"Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase\/AKT\/Bcl-XL activation and CD8+ T cell-mediated tumor eradication","volume":"18","author":"Zhong","year":"2010","journal-title":"Mol Ther"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1084\/jem.146.6.1719","article-title":"Suppression of human T-cell mitogenesis by prostaglandin. Existence of a prostaglandin-producing suppressor cell","volume":"146","author":"Goodwin","year":"1977","journal-title":"J Exp Med"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1007\/s00262-008-0494-5","article-title":"Cooperation of adenosine and prostaglandin E2 (PGE2) in amplification of cAMP-PKA signaling and immunosuppression","volume":"57","author":"Su","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"B99","doi-asserted-by":"publisher","first-page":"759","DOI":"10.4049\/jimmunol.1401710","article-title":"Coexpressed catalase protects chimeric antigen receptor\u2013redirected T cells as well as bystander cells from oxidative stress-induced loss of antitumor activity","volume":"196","author":"Ligtenberg","year":"2016","journal-title":"J Immunol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/1479-5876-10-127","article-title":"T cell receptor (TCR)-transgenic CD8 lymphocytes rendered insensitive to transforming growth factor beta (TGFbeta) signaling mediate superior tumor regression in an animal model of adoptive cell therapy","volume":"10","author":"Quatromoni","year":"2012","journal-title":"J Transl Med"},{"key":"B101","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/imr.12125","article-title":"Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma","volume":"257","author":"Chmielewski","year":"2014","journal-title":"Immunol Rev"},{"key":"B102","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","article-title":"IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression","volume":"71","author":"Chmielewski","year":"2011","journal-title":"Cancer Res"},{"key":"B103","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ymthe.2016.10.016","article-title":"Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer","volume":"25","author":"Mohammed","year":"2017","journal-title":"Mol Ther"},{"key":"B104","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00262-012-1378-2","article-title":"Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails","volume":"62","author":"Yang","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"B105","doi-asserted-by":"publisher","first-page":"e1100792","DOI":"10.1080\/2162402X.2015.1100792","article-title":"Commentary: IL-12 secreting tumor-targeted chimeric antigen receptor T cells: an unaddressed concern on Koneru","volume":"5","author":"Mirzaei","year":"2015","journal-title":"Oncoimmunology"},{"key":"B106","doi-asserted-by":"publisher","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","article-title":"Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning","volume":"119","author":"Pegram","year":"2012","journal-title":"Blood"},{"key":"B107","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1158\/1078-0432.CCR-11-3050","article-title":"Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice","volume":"18","author":"Chinnasamy","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B108","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1158\/1078-0432.CCR-13-1016","article-title":"Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition","volume":"20","author":"Perna","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B109","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.4049\/jimmunol.179.5.3332","article-title":"Tumor-derived chemokine MCP-1\/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells","volume":"179","author":"Brown","year":"2007","journal-title":"J Immunol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"B111","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1158\/0008-5472.CAN-06-3388","article-title":"High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer","volume":"67","author":"Piersma","year":"2007","journal-title":"Cancer Res"},{"key":"B112","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jneuroim.2013.08.013","article-title":"Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level","volume":"264","author":"Kmiecik","year":"2013","journal-title":"J Neuroimmunol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"5458","DOI":"10.1158\/1078-0432.CCR-10-0712","article-title":"Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses","volume":"16","author":"Peng","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B114","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","article-title":"T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model","volume":"113","author":"Di Stasi","year":"2009","journal-title":"Blood"},{"key":"B115","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1097\/CJI.0b013e3181ee6675","article-title":"Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b","volume":"33","author":"Craddock","year":"2010","journal-title":"J Immunother"},{"key":"B116","doi-asserted-by":"publisher","first-page":"e23564","DOI":"10.4161\/onci.23564","article-title":"Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors","volume":"2","author":"Spear","year":"2013","journal-title":"Oncoimmunology"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1158\/1078-0432.CCR-04-1524","article-title":"Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor","volume":"11","author":"van Herpen","year":"2005","journal-title":"Clin Cancer Res"},{"key":"B118","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1053\/j.seminoncol.2010.03.001","article-title":"Regional liver therapy using oncolytic virus to target hepatic colorectal metastases","volume":"37","author":"Carpenter","year":"2010","journal-title":"Semin Oncol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"5195","DOI":"10.1158\/0008-5472.CAN-14-0697","article-title":"Armed oncolytic virus enhances immune functions of chimeric antigen receptor\u2013modified T cells in solid tumors","volume":"74","author":"Nishio","year":"2014","journal-title":"Cancer Res"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N Engl J Med"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/nm.1882","article-title":"Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma","volume":"14","author":"Pule","year":"2008","journal-title":"Nat Med"},{"key":"B122","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nri3384","article-title":"Six-of-the-best: unique contributions of \u03b3\u03b4 T cells to immunology","volume":"13","author":"Vantourout","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B123","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1007\/s00018-011-0696-4","article-title":"\u03b3\u03b4 T-cells: cross-talk between innate and adaptive immunity","volume":"68","author":"Kabelitz","year":"2011","journal-title":"Cell Mol Life Sci"},{"key":"B124","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.it.2012.01.006","article-title":"Harnessing \u03b3\u03b4 T cells in anticancer immunotherapy","volume":"33","author":"Hannani","year":"2012","journal-title":"Trends Immunol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/sj.jid.5700003","article-title":"Immunosurveillance and immunoregulation by \u03b3\u03b4 T cells","volume":"126","author":"Girardi","year":"2006","journal-title":"J Invest Dermatol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1084\/jem.20101824","article-title":"Cutaneous immunosurveillance by self-renewing dermal \u03b3\u03b4 T cells","volume":"208","author":"Sumaria","year":"2011","journal-title":"J Exp Med"},{"key":"B127","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1126\/science.1110267","article-title":"Professional antigen-presentation function by human \u03b3\u03b4 T cells","volume":"309","author":"Brandes","year":"2005","journal-title":"Science"},{"key":"B128","doi-asserted-by":"publisher","first-page":"6195","DOI":"10.4049\/jimmunol.167.11.6195","article-title":"Human V\u03b32V\u03b42 T cells produce IFN-\u03b3 and TNF-\u03b1 with an on\/off\/on cycling pattern in response to live bacterial products","volume":"167","author":"Wang","year":"2001","journal-title":"J Immunol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/jid.2012.260","article-title":"CCR6 is required for epidermal trafficking of \u03b3\u03b4-T cells in an IL-23-induced model of psoriasiform dermatitis","volume":"133","author":"Mabuchi","year":"2013","journal-title":"J Invest Dermatol"},{"key":"B130","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/372190a0","article-title":"Adhesion between epithelial cells and T lymphocytes mediated by E-cadherin and the alpha E beta 7 integrin","volume":"372","author":"Cepek","year":"1994","journal-title":"Nature"},{"key":"B131","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.4049\/jimmunol.130.6.2615","article-title":"Immunohistologic and immunoelectron microscopic characterization of the mucosal lymphocytes of human small intestine by the use of monoclonal antibodies","volume":"130","author":"Cerf-Bensussan","year":"1983","journal-title":"J Immunol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s10549-009-0527-6","article-title":"Adoptively transferred ex vivo expanded \u03b3\u03b4-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer","volume":"122","author":"Beck","year":"2010","journal-title":"Breast Cancer Res Treat"}],"updated-by":[{"DOI":"10.3389\/fimmu.2019.00780","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T00:00:00Z","timestamp":1555459200000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2017.01850\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T04:47:20Z","timestamp":1693370840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2017.01850\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,22]]},"references-count":132,"alternative-id":["10.3389\/fimmu.2017.01850"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2017.01850","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fimmu.2019.00780","asserted-by":"object"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,22]]},"article-number":"1850"}}